NRAS or KRAS point mutations have been described in 25% of patients with JMML [29], and apart from a small portion of NRAS-mutated patients, somatic RAS mutations are usually associated with an aggressive disease course with a high rate of relapse after HSCT [5]. This evidence concerns the gene NRAS and juvenile myelomonocytic leukemia.